Triple Threat – 3x Retatrutide 10MG Research Pack

The Triple Threat pack supplies three separate 10mg lyophilized vials of Retatrutide (LY3437943), an investigational tri-agonist characterised in preclinical work as acting at the GLP-1, GIP, and glucagon receptors. The tri-agonist profile is what distinguishes it from single and dual incretin receptor agonists in the published metabolic literature. For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Triple Threat: 3x Retatrutide 10MG Research Bundle

This research bundle includes three (3) vials of Retatrutide 10MG, a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors. Retatrutide has generated significant interest in metabolic research due to its novel tri-agonist mechanism of action.

Bundle Contents

• 3x Retatrutide 10MG lyophilized powder
• Each vial independently tested for purity and identity

Research Context

Retatrutide (LY3437943) is a novel investigational compound studied for its simultaneous activity at three incretin-related receptors. Published Phase 2 trial data has demonstrated dose-dependent effects in preclinical and clinical research settings. This triple-agonist approach represents a distinct mechanism compared to single or dual-agonist compounds.

Certificates of Analysis

This is a bundle of separate vials, not a blend. Each compound is analysed on its own and carries its own batch certificate. One certificate never covers two different compounds unless they are supplied premixed in a single vial as a blend.

Third-party HPLC-UV testing by an independent third-party laboratory.

Storage

Store lyophilized powder at -20°C for long-term storage or 2-8°C for short-term. Protect from light and moisture.

Shipping

Same-day shipping on orders placed before 12 PM Pacific. Ships across Canada.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

For peer-reviewed research on this topic, visit PubMed.

Related Research Reading

Receptor-level background is covered in Retatrutide triple receptor agonism, and the pharmacological contrast against a single GLP-1 receptor agonist is set out in Semaglutide versus Retatrutide receptor comparison. Third-party analytical documentation is published on the Certificates of Analysis page.